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Ethnic minority disparities in progression
and mortality of pre-dialysis chronic kidney
disease: a systematic scoping review
Hilda O. Hounkpatin1*, Simon D. S. Fraser1, Rory Honney1, Gavin Dreyer2, Alison Brettle3 and Paul J. Roderick1
Abstract
Background: There are a growing number of studies on ethnic differences in progression and mortality for pre-
dialysis chronic kidney disease (CKD), but this literature has yet to be synthesised, particularly for studies on
mortality.
Methods: This scoping review synthesized existing literature on ethnic differences in progression and mortality for
adults with pre-dialysis CKD, explored factors contributing to these differences, and identified gaps in the literature.
A comprehensive search strategy using search terms for ethnicity and CKD was taken to identify potentially relevant
studies. Nine databases were searched from 1992 to June 2017, with an updated search in February 2020.
Results: 8059 articles were identified and screened. Fifty-five studies (2 systematic review, 7 non-systematic reviews,
and 46 individual studies) were included in this review. Most were US studies and compared African-American/Afro-
Caribbean and Caucasian populations, and fewer studies assessed outcomes for Hispanics and Asians. Most studies
reported higher risk of CKD progression in Afro-Caribbean/African-Americans, Hispanics, and Asians, lower risk of
mortality for Asians, and mixed findings on risk of mortality for Afro-Caribbean/African-Americans and Hispanics,
compared to Caucasians. Biological factors such as hypertension, diabetes, and cardiovascular disease contributed
to increased risk of progression for ethnic minorities but did not increase risk of mortality in these groups.
Conclusions: Higher rates of renal replacement therapy among ethnic minorities may be partly due to increased
risk of progression and reduced mortality in these groups. The review identifies gaps in the literature and highlights
a need for a more structured approach by researchers that would allow higher confidence in single studies and
better harmonization of data across studies to advance our understanding of CKD progression and mortality.
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Background
Chronic kidney disease (CKD) is common and is associ-
ated with increased morbidity and mortality [1–3]. Risk
factors for progression include proteinuria, comorbid
conditions such as diabetes and cardiovascular disease,
as well as non-modifiable characteristics such as ethni-
city [4, 5]. In the UK, a higher proportion of people from
ethnic minority groups than Caucasians begin renal re-
placement therapy (RRT) [6]. In the United States (US),
the rate of RRT initiation for end-stage kidney disease
(ESKD) is also disproportionately higher for ethnic
minority groups (such as African-American, Hispanic
and Native Americans) compared to Caucasians, despite
similar prevalence for early stages of CKD [7]. Higher
RRT prevalence in ethnic minority groups has been
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attributed to faster progression of CKD and better CKD
survival [7, 8]. Understanding which ethnic groups have
worse outcomes and which factors influence adverse
outcomes can help clinicians and policy makers target
health care efforts and resources and improve outcomes
for individuals, as well as inform policies to reduce
health inequities.
To our knowledge, no study has systematically scoped
studies exploring the range of risk factors for ethnic dif-
ferences in CKD progression and mortality. A systematic
review published in 2010 [9] that investigated ethnic dif-
ferences in CKD progression, and had similar inclusion
criteria to the current study, identified 5 relevant studies
and concluded little evidence for ethnic differences in
CKD progression and a lack of appropriately designed
studies to assess ethnic differences in CKD progression.
However, there have since been further studies in the
field. Furthermore, no studies have systematically syn-
thesised evidence for ethnic differences in mortality for
people with pre-dialysis CKD, which would further con-
tribute to understanding of ethnic differences in CKD
progression – a competing risk. A scoping review rapidly
examines the extent, range, and nature of existing know-
ledge in a diverse body of literature, summarises re-
search findings and identifies research gaps [10]. In
contrast to systematic reviews, scoping reviews identify
and synthesise the breadth of knowledge in a given area
without in depth assessment of study quality. The aim of
this scoping review was to identify and present findings
from studies addressing ethnic differences in pre-dialysis
CKD progression and mortality, the key factors that
underpin these ethnic differences, and identify areas
where further research is needed. Understanding the
patterns and potential mechanisms in ethnic minorities
in high-income countries may contribute to CKD preven-
tion and care in countries where they are the main ethnic
groups. We conducted a scoping review to synthesize the
existing literature comparing CKD progression and mor-
tality for ethnic minority and non-ethnic minority adults
with pre-dialysis CKD.
Methods
Our scoping review was conducted in line with the five-
stage framework outlined by Arskey and O’Malley (2005)
[10]. This framework includes formulating the research
question, identifying relevant studies, study selection, chart-
ing the data, and collating, summarizing and reporting re-
sults. We acknowledge that classification of ethnicity can be
complex and challenging. In this study, ethnic minority was
defined as belonging to a particular group of people with
common social, physical, national, linguistic, cultural, an-
cestral backgrounds and other such attributes living in a
country where they differ from the majority [11]. Ethnic
minority groups include African-Americans, Hispanic,
Asian (East Asia, Southeast Asia, Indian subcontinent), Na-
tive Hawaiian or Pacific Islanders, and American Indian or
Alaska Native in US studies, and Afro-Caribbean, South
Asian (comprising Indians, Pakistanis, Bangladeshis), East
Asians [e.g.: Chinese], and other Asian countries, and First
Nation populations in UK and other countries [e.g.:
Aboriginal Australians]. Pre-dialysis CKD was defined
by glomerular filtration rate (GFR) or a combination
of urinary albumin to creatinine ratio and GFR, and
not requiring RRT.
Information sources and search strategies
Search terms for ethnic groups included ‘ethnic groups,
race, minority, Asian, Caucasian, Hispanic, Continental
population groups, and African’ [11]. Search terms for
CKD included ‘kidney diseases, renal insufficiency, glom-
erular filtration rate’. Searches were expanded using
truncation symbols and search terms were combined
using Boolean operators. The electronic databases Med-
line OVID, Embase, CINAHL, PsycINFO, Web of Sci-
ence, Scopus, Social Care Online, Applied Social
Sciences Index and Abstracts (ASSIA), and Cochrane
Database of Promoting Health Effectiveness Reviews
were searched from 1992 to July 2017. An updated
search was conducted in February 2020 to identify more
recent eligible studies. A time frame of 1992 onwards
was set to capture evidence from the last 28 years and
the searches were limited to the English language.
Searches were conducted without a study design filter.
Bibliography searches of key papers were performed.
The search strategies for each database can be found in
Appendix 1.
Article selection
A comprehensive and iterative approach to the literature
searches for evidence was taken to ensure that a broad
range of perspectives was captured. Articles were in-
cluded in the review if the following criteria were met:
(1) used an adult study population and (2) compared risk
of progression [e.g., (decline in) (estimated) glomerular
filtration rate (GFR)] and/or mortality for ≥2 ethnic
groups with pre-dialysis CKD. Articles that did not com-
pare outcomes between ethnic minority and non-ethnic
minority groups or focused on dialysis/transplant pa-
tients were excluded. Two reviewers (HH and RH)
reviewed articles to determine eligibility for inclusion.
Any discrepancies were resolved by discussion with a
third reviewer (SF).
Data extraction and synthesis
Data were extracted into a series of evidence tables, de-
veloped a priori, by one reviewer (HH). One evidence
table was produced for each outcome group. Each table
included details on the authors, date of publication,
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country in which the study was conducted, study aims,
ethnic groups included in the study, study design, out-
comes of interest, and key findings on factors associated
with any ethnic differences in CKD outcomes for each
study. Evidence tables can be found in Appendix 2. A
narrative synthesis approach was taken to summarise
the evidence.
Results
Search strategy, study selection and data extraction
The results of the search strategy and selection process
are shown in Fig. 1. 8059 citations were identified from
the search. After removing duplicates and title and ab-
stract screening 227 studies met the criteria for full text
review, from which 50 were selected for inclusion in the
review. Our updated searches identified 5 relevant stud-
ies published between July 2017 and February 2020,
resulting in a total of 55 studies included in the review.
These 55 studies included 1 systematic review [9] and 8
literature reviews on CKD progression [12–19]. Together
these reviews included 19 of the individual studies identi-
fied in our searches. The reviews were published between
2004 and 2018, addressed slightly different research ques-
tions, and included different studies (Table 1). Only two
of the reviews [9, 19] used a systematic search strategy
and reported clear inclusion/exclusion criteria. Forty-two
studies (n = 15,204,453 individuals; median: 3785, IQR:
1208-25,774) examined differences in CKD progression
and thirty studies (n = 4,480,316 individuals, median:
3939, IQR: 1798-22,634) assessed ethnic differences in
survival.
Ethnic differences in CKD progression
African-Americans and Afro-Caribbean ethnicity
Thirty-six studies explored CKD progression for African-
Americans or Afro-Caribbeans and Caucasians (Table 2).
Studies were conducted in the US, Canada, UK, and
Norway and most were prospective or retrospective cohort
studies. Overall, most (n = 24) studies reported higher risk
of CKD progression in African-American/Afro-Caribbean
Fig. 1 Flow diagram of searching and selection process
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Table 2 Summary of studies on ethnic differences in CKD progression
Comparison group
(number of studies)
Country
of study
Number
of studies
Studies Study design Finding Summary findings
African-American/
Afro-Caribbean (AA)
vs Caucasian (n = 36)
US 29 Agarwal et al., 2008 Prospective cohort study Higher risk for AA 24 studies reported higher
risk for AA, 12 studies found
no significant differencesAlves et al., 2010 Retrospective cohort study Higher risk for AA
Babayev et al., 2013 Prospective cohort study Higher risk for AA
Chen et al., 2018 Commentary Higher risk for AA
Choi et al., 2009 Prospective cohort study Higher risk for AA
Crews et al., 2014 Literature review Higher risk for AA
Crews et al., 2018 Prospective cohort study Higher risk for AA
Derose et al., 2013 Retrospective cohort study Higher risk for AA
Fischer et al., 2016 Prospective cohort study Similar risk
Grams et al., 2017 Prospective cohort study Similar risk
Go et al., 2018 Retrospective cohort study Similar risk
Hall et al., 2010 Prospective cohort study Higher risk for AA
Harding et al., 2017 Literature review Higher risk for AA
Hebert et al., 1997 Randomized clinical trial Similar risk
Horowitz et al., 2015 Literature review Higher risk for AA
Hsu et al., 2003 Birth cohort analysis Higher risk for AA
Hsu et al., 2005 Prospective cohort study Higher risk for AA
Hunsicker et al., 1997 Randomized prospective trial Higher risk for AA
Jawadi et al., 2018 Systematic review and meta-
analysis
Higher risk for AA
Jolly et al., 2014 Prospective cohort study Similar risk
Jones-Burton et al., 2005 Prospective cohort study Higher risk for AA
Kovesdy et al., 2009 Prospective cohort study Similar risk
Lewis et al., 2015 Randomized, double-blind,
placebo-controlled study
Higher risk for AA
Lucas et al., 2008 Prospective cohort study Higher risk for AA
Menon et al., 2008 Retrospective cohort study Similar risk
Norris et al., 2008 Commentary/review Higher risk for AA
Parsa et al., 2013 Prospective cohort study Higher risk for AA
Salifu et al., 2009 Prospective cohort study Similar risk
Yang et al., 2014 Prospective cohort study Higher risk for AA
Canada 1 Barbour et al., 2010 Systematic review Similar risk
UK 5 Ali et al., 2013 Prospective cohort study Similar risk
Dreyer et al., 2013 Retrospective cohort study Higher risk for AA
Earle et al., 2001 Retrospective case-note
review
Similar risk
Hull et al., 2011 Cross-sectional study Similar risk
Mathur et al., 2018 Prospective cohort study with
nested case-control study
Higher risk for AA
Norway 1 Van den Beukel et al., 2013 Prospective cohort study Higher risk for AA
South Asian
(SA) (n = 12)
US 4 Hall et al., 2010 Prospective cohort study Higher risk for SA 6 studies reported similar risk
for SA compared to Caucasians,
6 reported higher risk for SADerose et al., 2013 Retrospective cohort study Higher risk for SA
Lewis et al., 2015 Randomized, double-blind,
placebo-controlled study
Similar risk
Jawadi et al., 2018 Systematic review and
meta-analysis
Similar risk
Canada 1 Barbour et al., 2010 Prospective cohort study Similar risk
UK 7 Ali et al., 2013 Prospective cohort study Similar risk
Dreyer et al., 2013 Retrospective cohort study Higher risk for SA
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(adjusted (for varying covariates) HRs ranging in 15 studies
from 1.16 (95% CI: 1.09–2.62) to 4.00 (95% CI: 2.99–5.35))
[13–16, 19–38]. However, some (n = 12) studies found no
significant ethnic differences in risk of CKD progression,
which may be partly due to smaller study sample size, dur-
ation of follow up, and/or adjustment for confounders and
mediators [9, 38–48]. Studies adjusted for demographics
factors (such as age and sex, with fewer studies adjusting
for socioeconomic status), biological factors (such as base-
line estimated glomerular filtration (eGFR) levels, protein-
uria, baseline creatinine, cholesterol, haemoglobin, blood
pressure), comorbidities (hypertension, diabetes, cardiovas-
cular disease). Some studies also adjusted for body mass
index, smoking, and prescribed medication.
Lower baseline eGFR levels [23, 25, 34], proteinuria
[34, 35], albuminuria [26], and higher (treated) blood
pressure [31, 41, 48], and glycaemic control [45, 47] pre-
dicted increased risk of progression in African-
Americans compared to Caucasians. Existing diabetes,
cardiovascular diseases and congestive heart failure ei-
ther fully or partially attenuated the association of in-
creased risk of progression observed for African-
Americans [26, 31, 43] compared to Caucasians. Apoli-
poprotein E and variants in the gene encoding apolipo-
protein L1 (APOL1) explained some differences in
progression for African-Americans compared to Cauca-
sians [28, 33]. For example, there was a mean adjusted dif-
ference in eGFR slope of − 1.05ml per minute per 1.73m2
per year (p < 0.001) for African-Americans in the high risk
APOL1 group compared to Caucasians but no significant
difference between rate of eGFR decline for African-
Americans in the low risk APOL1 group and Caucasians
[33].
South Asians
Twelve studies explored CKD progression in South
Asians [18, 25, 26, 31, 35, 36, 46–51]. These studies were
conducted in the US, Canada, and UK. Most were
Table 2 Summary of studies on ethnic differences in CKD progression (Continued)
Comparison group
(number of studies)
Country
of study
Number
of studies
Studies Study design Finding Summary findings
Earle et al., 2001 Retrospective case-note
review
Higher risk for SA
Hull et al., 2011 Cross-sectional study Higher risk for SA
Koppiker et al., 1998 Retrospective case review Similar risk
Mathur et al., 2018 Prospective cohort study
with nested case-control study
Higher risk for SA
Pallayova et al., 2015 Prospective cohort study Similar risk
East Asian (EA)
(n = 4)
US 3 Hall et al., 2010 Prospective cohort study Higher risk for EA 3 studies reported higher risk
for EA, 1 reported no
significant differencesDerose et al., 2013 Retrospective cohort study Higher risk for EA
Lewis et al., 2015 Randomized, double-blind,
placebo-controlled study
Similar risk
Canada 1 Barbour et al., 2010 Prospective cohort study Higher risk for EA
Asian - Pacific
Islander (PI) (n = 4)
US 4 Derose et al., 2013 Retrospective cohort study Higher risk for PI 2 studies reported higher risk
for PI, 2 reported no
significant differencesGo et al., 2018 Retrospective cohort study Similar risk
Hall et al., 2010 Prospective cohort study Higher risk for PI
Lewis et al., 2015 Randomized, double-blind,
placebo-controlled study
Similar risk
Hispanic (n = 7) US 6 Derose et al., 2013 Retrospective cohort study Higher risk for Hispanics 6 studies reported higher
risk for Hispanics, 1 reported
similar riskFischer et al., 2016 Prospective cohort study Higher risk for Hispanics
Hall et al., 2010 Prospective cohort study Higher risk for Hispanics
Horowitz et al., 2015 Literature review Higher risk for Hispanics
Lewis et al., 2015 Randomized, double-blind,
placebo-controlled study
Higher risk for Hispanics
Peralta et al., 2006 Prospective cohort study Higher risk for Hispanics
Canada 1 Barbour et al., 2010 Systematic review Similar risk
Native American
(n = 2)
US 2 Go et al., 2018 Retrospective cohort study Similar risk
Lewis et al., 2015 Randomized, double-blind,
placebo-controlled study
Similar risk 2 studies reported similar risk
Indigenous
populations (n = 2)
Australia 1 Cass et al., 2004 Discussion paper Higher risk for indigenous
populations
Both studies reported higher
risk
Canada 1 Samuel et al., 2014 Prospective cohort study Higher risk for indigenous
populations
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prospective or retrospective studies. Six studies reported
similar risk of progression for South Asians compared to
Caucasians and 6 reported higher risk for South Asians
(for example 2 studies reported odds ratios (95%CI) of
1.44 (1.00–1.85) and 1.41 (1.32–1.51). Studies adjusted
for demographic, biological factors, comorbidities, smok-
ing, and prescribed medication and indicated eGFR
levels [25], proteinuria [34, 35], higher (treated) blood
pressure [48], and renal comorbidities [49] may explain
these ethnic differences.
East Asians
Four studies explored CKD progression in East Asians,
of which 3 were conducted in the US and 1 in Canada.
Three were cohort studies and 1 was a randomised con-
trolled trial (RCT). Three studies found higher risk for
East Asians (one study reporting adjusted OR (95% CI):
1.41 (1.32–1.51)) and 1 study found similar risk of pro-
gression for East Asians compared to Caucasians [25, 26,
31, 49]. Studies adjusted for demographic, biological and
comorbid factors. There was some evidence that renal
comorbidities [31, 49] may contribute to South Asians
having higher risk of CKD progression that Caucasians.
Pacific islanders
Four US studies included Pacific Islanders [25, 26, 31, 40].
One was a prospective cohort study, 2 retrospective cohort
studies, and 1 RCT. Two studies reported higher risk of
CKD progression for Pacific Islanders - 1 study reporting
adjusted OR (95% CI): 1.41 (1.32–1.51) and another study
reporting adjusted HR (95% CI): 3.84 (2.73–5.40), and 1
study found no significant differences in CKD progression
for Pacific Islanders compared to Caucasians (adjusted OR
(95% CI): 1.02 (0.91–1.15)). Factors contributing to ethnic
differences in CKD progression for Pacific Islanders com-
pared to Caucasians were unclear/unexplored.
Hispanics
Seven studies compared CKD progression for Hispanics
and Caucasians. Six were conducted in the UK and 1 in
Canada. Four were prospective or retrospective cohort
studies, 2 were reviews and 1 was an RCT. Six studies
reported higher risk of CKD progression for Hispanics
compared to Caucasians (effect estimates ranging from
adjusted HR (95% CI): 1.93 (1.72–2.17) to HR (95% CI):
2.20 (1.46–3.30), and adjusted OR (95% CI): 1.49 (1.42–
1.56)) [15, 25, 26, 31, 38, 52]. One study reported similar
risk [9]. Studies suggested eGFR levels [25, 31], albumin-
uria [26], body mass index [31], blood pressure [31], dia-
betes [38], and prior cardiovascular disease [31] may
explain the higher risk of CKD progression observed for
Hispanics.
Native Americans
Two US studies explored CKD progression for Native
Americans: 1 retrospective cohort study and 1 RCT.
Both studies reported similar risk for CKD progression
for Native Americans compared to Caucasians (for ex-
ample, Go et al. (2018) reported adjusted OR (95% CI):
1.57 (0.81–3.04)) [31, 40].
Indigenous populations
Two studies, 1 conducted in Australia and 1 in Canada,
focused on CKD progression in Indigenous populations
[17, 53]. One was a discussion paper and the other a
prospective cohort study. Both studies reported higher
risk of CKD progression for Indigenous populations
compared to Caucasians. Samuel et al. (2014) reported
adjusted HR (95% CI): 18.67 (10.77–32.36) vs 6.33
(5.41–7.40) for First Nation vs non First Nation individ-
uals, respectively. The discussion paper explored path-
ways through which socioeconomic factors explained
these differences.
Ethnic disparities in all-cause mortality
African-Americans and afro-Caribbeans
Twenty-seven studies examined mortality differences for
African-American or Afro-Caribbeans compared to
Caucasians (Table 3). Most were conducted in the US
and were either prospective or retrospective cohort stud-
ies. Eighteen studies reported no significant ethnic dif-
ferences in survival [20–22, 26, 33, 34, 36, 38, 39, 42, 44,
46, 54–59]. Five studies found higher risk of mortality
for African-Americans [13, 23, 60–62] (adjusted HRs
(95% CI) ranging in studies from 1.30 (1.02–1.65) to
1.83 (1.33–2.52)), and 4 reported lower risk of mortality
for African-Americans [25, 43, 63, 64] (adjusted HRs
(95% CI) ranging in studies from 0.67 (0.63–0.72) to
0.79 (0.61–0.97)). Studies suggested age [25, 63], bio-
logical factors (e.g., higher blood pressure, serum albumin),
comorbidities (cardiovascular disease, diabetes) and medi-
cation use (e.g.; more frequent use of calcitriol and less use
of statins in African-Americans compared to Caucasians)
[43, 63] may partly explain ethnic differences in survival for
African-Americans/Afro-Caribbeans and Caucasians with
CKD. There were mixed findings on the role of socioeco-
nomic status in explaining these differences [60, 61].
South Asians
Eight studies explored ethnic differences in mortality for
South Asians compared to Caucasians. Studies were con-
ducted in the US (n = 4), Canada (n = 2), and UK (n = 2).
All were either retrospective or prospective cohort studies.
Six reported lower risk of mortality for South Asians com-
pared to Caucasians (adjusted HR (95% CI) ranging from
0.33 (0.14–0.64) to 0.73 (0.59–0.88)), and 2 reported no
significant differences (e.g., OR (95% CI): − 0.51 (− 3.25 to
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Table 3 Summary of studies on ethnic differences in mortality for individuals with CKD
Comparison group
(number of studies)
Country
of study
Number of
studies
Studies Study design Finding Summary findings
African-American/
Afro-Caribbean (AA)
vs Caucasian (n = 27)
US 24 Agarwal et al., 2008 Prospective cohort study Similar risk 5 studies reported higher risk
for AA, 4 studies reported lower
risk, 18 studies found no
significant differences
Alves et al., 2010 Retrospective cohort study Similar risk
Babayev et al., 2013 Prospective cohort study Similar risk
Cardarelli et al., 2008 Prospective cohort study Similar risk
Choi et al., 2009 Prospective cohort study Higher risk for AA
Derose et al., 2013 Retrospective cohort study Lower risk for AA
Fedewa et al., 2014 Prospective cohort study Higher risk for AA
Fischer et al., 2016 Prospective cohort study Similar risk
Grams et al., 2017 Prospective cohort study Similar risk
Hall et al., 2010 Prospective cohort study Similar risk
Hayes et al., 2012 Prospective cohort study Similar risk
Jolly et al., 2011 Retrospective cohort study Similar risk
Jolly et al., 2014 Prospective cohort study Similar risk
Kovesdy et al., 2009 Prospective cohort study Lower risk for AA
Kovesdy et al., 2013 Historical cohort Lower risk for AA
Mehrotra et al., 2008 Prospective cohort study Higher risk for AA
Menon et al., 2008 Retrospective cohort study Similar risk
Navaneethan et al.,
2011
Retrospective cohort study Similar risk
Newsome et al., 2006 Retrospective cohort study Lower risk for AA
Norris et al., 2008 Commentary/review Higher risk for AA
Parsa et al., 2013 Prospective cohort study Similar risk
Weiner et al., 2004 Retrospective cohort study Higher risk for AA
Wetmore et al., 2011 Prospective cohort study Similar risk
Yang et al., 2014 Prospective cohort study Similar risk
UK 3 Ali et al., 2013 Prospective cohort study Similar risk
Hutchison et al., 2014 Prospective cohort study Similar risk
Mathur et al., 2018 Prospective cohort study
with nested case-control
study
Similar risk
South Asian (SA)
(n = 8)
US 3 Derose et al., 2013 Retrospective cohort study Lower risk for SA 6 studies reported lower risk
for SA compared to Caucasians,
2 reported no significant
differences
Hall et al., 2010 Prospective cohort study Lower risk for SA
Jolly et al., 2011 Retrospective cohort study Lower risk for SA
Canada 2 Barbour et al., 2010 Prospective cohort study Similar risk
Conley et al., 2012 Prospective cohort study Lower risk for SA
UK 3 Ali et al., 2013 Prospective cohort study Similar risk
Hutchison et al., 2014 Prospective cohort study Lower risk for SA
Mathur et al., 2018 Prospective cohort study
with nested case-control study
Lower risk for SA
East Asian (EA)
(n = 5)
US 3 Derose et al., 2013 Retrospective cohort study Lower risk for EA All studies reported lower risk
for EA
Hall et al., 2010 Prospective cohort study Lower risk
Jolly et al., 2011 Retrospective cohort study Lower risk for EA
Canada 2 Barbour et al., 2010 Prospective cohort study Lower risk for EA
Conley et al., 2012 Prospective cohort study Lower risk for EA
Asian - Pacific
Islander (PI) (n = 3)
US 3 Derose et al., 2013 Retrospective cohort study Lower risk for PI 2 studies reported lower risk
for PI, 1 reported no significant
differencesHall et al., 2010 Prospective cohort study Similar risk
Jolly et al., 2011 Retrospective cohort study Lower risk for PI
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− 2.23)) [33, 34, 36, 46, 49, 56, 59, 65]. Studies that re-
ported lower risk of mortality for South Asians suggested
age and sex, proteinuria, blood pressure, diabetes, cardio-
vascular disease and medications (antihypertensive drugs
and statins), and C-reactive protein partly explained ethnic
differences in mortality [49, 59].
East Asians
Five cohort studies – 3 conducted in the US and 2 in
Canada- explored mortality differences for East Asians
and Caucasians. All 5 studies reported lower risk of
mortality for East Asians compared to Caucasians (ad-
justed HR (95% CI) ranging from 0.58 (0.52–0.65) to
0.69 (0.55–0.88)) [25, 26, 49, 56, 65]. Age and sex, pro-
teinuria, blood pressure, diabetes, cardiovascular disease
and medications (antihypertensive drugs and statins),
and C-reactive protein [49, 59] partly explained the
lower risk of mortality observed for East Asians.
Pacific islanders
Three US studies, 1 prospective and 2 retrospective co-
hort studies, explored mortality differences for Asians/
Pacific Islanders and Caucasians [25, 26, 56]. Two re-
ported lower risk of mortality for Pacific Islanders (ad-
justed HR (95% CI) ranging from 0.58 (0.52–0.65) to
0.76 (0.61–0.95) and 1 reported no significant differ-
ences. Factors contributing to ethnic differences in mor-
tality for Pacific Islanders compared to Caucasians were
not fully explored.
Hispanics
Six US studies examined ethnic differences in mortality
for Hispanics and Caucasians [25, 26, 38, 52, 56, 61].
Studies were either prospective or retrospective cohort
studies. Three studies reported lower risk of mortality
for Hispanics compared to Caucasians (adjusted HR
(95% CI) ranging from 0.66 (0.50–0.94) to 0.72 (0.66–
0.79)) and 3 reported similar risk (adjusted HR (95% CI)
ranging from 0.79 (0.59–1.35) to 0.94 (0.74–1.20)).
Lower risk of mortality observed for Hispanics was
partly explained by differences in urine protein levels
[38] (with Hispanics having significantly lower risk of
mortality than Caucasians at higher levels of urine pro-
tein but no significant ethnic differences at lower levels
of urine protein) and not explained by differences in
hypertension, diabetes, and use of medication including
insulin [52].
Native Americans
One US retrospective cohort study compared mortality
differences for Native Americans and Caucasians and re-
ported higher risk of mortality for Native Americans
(adjusted HR (95% CI):1.41 (1.08–1.84)) [56]. Factors
contributing to mortality differences for Native Ameri-
cans compared to Caucasians were not clear.
Discussion
We used an established and systematic methodology and
searched a range of databases to capture the full range
of existing studies on ethnic differences in pre-dialysis
CKD progression and mortality. This scoping review
identified evidence for higher risk of CKD progression in
Afro-Caribbean/African-Americans, Hispanics, Asians
compared to Caucasians which was at least partly ex-
plained by biological factors (e.g.: blood pressure) and
comorbidities (such as diabetes, and cardiovascular dis-
ease), and lower risk of mortality for South and East
Asians and Pacific Islanders compared to Caucasians.
Our scoping review also identified mixed findings on
risk of mortality for African-Americans and Hispanics
compared to Caucasians. Future studies need to explore
this, as studies reporting significant findings did not dif-
fer in the range of adjusted confounders compared to
studies that found significant differences. The role of
medication in the association between ethnicity and pro-
gression and mortality is complex, as differences in
medication may represent unmet need in certain ethnic
Table 3 Summary of studies on ethnic differences in mortality for individuals with CKD (Continued)
Comparison group
(number of studies)
Country
of study
Number of
studies
Studies Study design Finding Summary findings
Hispanic (n = 6) US 6 Derose et al., 2013 Retrospective cohort study Lower risk for
Hispanics
3 studies reported lower risk
for Hispanics, 3 studies reported
similar risk
Fischer et al., 2016 Prospective cohort study Similar risk
Hall et al., 2010 Prospective cohort study Similar risk
Jolly et al., 2011 Retrospective cohort study Lower risk for
Hispanics
Peralta et al., 2006 Prospective cohort study Lower risk for
Hispanics
Mehrotra et al., 2008 Prospective cohort study Similar risk
Native American
(n = 1)
US 1 Jolly et al., 2011 Retrospective cohort study Higher risk for Natives 1 study reported higher risk
for Native Americans
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groups or may be an indicator of disease severity in
individuals.
Gaps in the literature
A key gap in this literature is understanding why Asians
(South, East, and Pacific Islanders) and Hispanics live
longer, despite having higher prevalence of comorbidities
such as diabetes, cardiovascular disease, and heart fail-
ure. Future research may explore potential missing fac-
tors that may explain why these groups experience
increased risk CKD progression but live longer. The
search also identified most research on ethnic differ-
ences in CKD progression and mortality has been con-
ducted in US populations and there is less research in
other countries with a significant proportion of ethnic
minority immigrant populations (e.g.: UK, Canada), as
well as lower/middle income countries. Across all stud-
ies, comparisons were made mostly between Caucasians
vs. African-Americans and Caucasians vs. Hispanic (in
US studies), and Caucasians vs. Afro-Caribbean and
Caucasian vs. South Asian (in UK studies). Fewer studies
compared Caucasians to East Asians, Pacific Islanders or
Native Americans. Furthermore, most studies did not
distinguish between subgroups within an ethnic group
(e.g.: Africans vs. Caribbean in the same ethnic group).
There may be heterogeneity in findings within ethnic
groups, as shown in a recent UK study that found risk of
CKD progression was higher in Bangladeshis compared
to Indians [36]. Similarly, identified studies did not dis-
tinguish or adjust for generational status or indigenous
vs immigrant populations, though some existing studies
may not have been captured through our searches.
Some studies did not adjust for important confounders
of the association between ethnicity and CKD outcomes.
Firstly, very few (n = 15) of the included studies adjusted
for socioeconomic status. This is particularly important
for US studies, where low socioeconomic status is closely
linked to ethnicity and independently associated with
health insurance and access to health care. Secondly,
most studies on CKD progression did not account for
competing risk of death, so differences in progression in
these studies may have been at least partly due to differ-
ences in survival across ethnic groups. A limited number
of studies (n = 18) assessed ethnic differences in both
progression and mortality. These studies seemed to sug-
gest Hispanics and East and South Asians experience in-
creased risk of CKD progression as result of lower
competing risk of death, and poorer evidence for signifi-
cant differences in risk of mortality for African-Americans
and Hispanics compared to Caucasians. However, further
research is needed to confirm these findings. Thirdly,
there were few studies exploring genetic risk factors for
CKD progression and mortality. Some studies have sug-
gested other genetic risk factors such as genes encoding
non-muscle myosin heavy chain type II isoform A for
ESKD in African-Americans [66], but there is a lack of
genetic studies comparing risk of ESKD across different
ethnic groups with pre-dialysis CKD. Future studies may
also explore whether differences between ethnic groups
hold across countries or whether they differ due to societal
and health care reforms. Fourthly, some studies did not as-
sess progression and mortality stratified by level of CKD se-
verity, making it difficult to directly compare or identify if
ethnic differences in progression and mortality vary at dif-
ferent stages of CKD. An updated systematic review and
meta-analysis that goes beyond scoping to assess bias in
these studies and pool together estimates from the different
studies (where possible) may help explain some of the
mixed findings and improve our understanding of the ex-
tent and key predictors of ethnic differences in CKD out-
comes. Finally, there was lack of data on level of control of
biologic factors such as blood pressure and glycemia, as
well as limited data on medication and adherence, and how
these vary across ethnic groups, all of which are important
for differences in CKD progression and mortality. Future
studies should aim to capture this data as much as possible.
Limitations
The review was based on a comprehensive search of the
literature. However, it is possible that some relevant
studies may have been missed as the search was re-
stricted to studies that were published in English and
published after 1992. Studies that examined CKD pro-
gression and outcomes for only one ethnic group and
did not make comparisons with another ethnic group
were also excluded. Furthermore, there was limited add-
itional searching of grey literature, though we believe the
majority of relevant studies will have been captured
through the different databases and bibliography.
An important limitation of the scoping review ap-
proach is that papers are not critically appraised in detail
and quality of the individual studies is therefore not
assessed [10]. However, this scoping review was based
on established methodology [10] and has mapped the
existing literature on ethnic differences in CKD out-
comes, identified gaps in the research and highlighted
the need for further systematic reviews and additional
primary research focusing on cardiovascular-related and
other adverse outcomes for pre-dialysis CKD.
Clinical and policy implications of this scoping review
Increased risk of CKD progression in ethnic minority
groups may be tackled through closer monitoring and
management of renal comorbidities such as diabetes and
cardiovascular disease, for example through proteinuria
and blood pressure measurement, particularly in these
high risk groups. There has been some evidence to sug-
gest incentivisation programs, such as the Quality and
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Outcomes Framework programme in the UK, may help
improve care for diabetics with CKD [67]. Interventions
including the use of medications such as renin-
angiotensin-aldosterone system blockers and patient-
provider education interventions may also reduce risk of
progression in high-risk groups [68]. In the UK, a na-
tional quality improvement programme has mapped la-
boratory data taken from all settings to derive graphs of
kidney function over time. Declining kidney function is
then flagged by a laboratory scientist and sent to primary
care doctor for clinical review and referral, where neces-
sary [69]. However, a better understanding of risk factors
for CKD progression in high risk groups is needed to
help develop more effective and targeted interventions.
Conclusions
Scoping reviews are a relatively novel method of system-
atically assessing a wide range of literature in a particular
field, in order to identify important gaps in the literature,
and inform more targeted systematic reviews or further
studies. This is the first synthesis of the extensive body
of literatures on ethnic differences in CKD progression
and mortality. The findings of this review suggest higher
rates of RRT in ethnic minority groups may be partly
due to increased risk of progression and reduced mortal-
ity in these groups (compared to Caucasians), though
more evidence is needed for African-American and
Hispanic ethnicity. The review highlights the need for
further studies using similar approaches and adjusting
for the same confounders, which would improve our un-
derstanding of disease progression and mortality in
people with CKD.
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